Product logins

Find logins to all Clarivate products below.


Kidney Transplant | Treatment Algorithms: Claims Data Analysis | US | 2021

MARKET OUTLOOK

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. However, these powerful agents come with considerable risks on top of their important benefits. This report examines how key immunosuppressive agents are used in induction and maintenance regimens for kidney transplant rejection prophylaxis.

Questions AnsweredUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in the induction and maintenance phases? What are the quarterly trends in prescribing among induction- and maintenance-phase kidney transplant patients?
  • How have different immunosuppressive agents been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of kidney transplant patients switch to a different therapy after initiation and how quickly?
  • What percentage of kidney transplant patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

 

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Content Highlights

 

Markets covered: United States.

Key companies: BMS, Novartis, Pfizer, Roche, Sanofi Genzyme, Teva.

Key drugs: Nulojix, Imuran, CellCept, Myfortic, Prograf, Astagraf XL, Envarsus XR, Neoral, Sandimmune, Rapamune, Zortress, Thymoglobulin, Atgam, Simulect.

Product DescriptionRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…
Report
Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer
The breast cancer therapy market in mainland China is one of the most dynamic in the oncology sector. Several new and emerging therapies are expected to gain approval for specific subpopulations,…
Report
Human Immunodeficiency Virus – Current treatment – Treatment Algorithms: Claims Data Analysis – Human Immunodeficiency Virus (US)
The HIV therapy market is crowded with many approved ARVs. Market growth is driven by the increasing acceptance of new, high-priced ARVs, particularly the latest STRs, that offer improved safety,…